List view / Grid view
Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.
Researchers have found a protein that, when inhibited in mice with cancer, increased the response to immunotherapy.
Scientists have discovered that hepatic stellate cells are key in allowing dormant cancer cells to awaken and form fatal metastases.
Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
Scientists have developed six new derivatives of 4-chloro-1,2-dithiol-3-thione, which have all demonstrated anticancer effects in pre-clinical studies.
Chimeric antigen receptor (CAR) T and natural killer (NK) therapies may become the future of cancer treatment. Dr Jim Ross explains how bioelectronic assays are a non-invasive, label-free approach built for real-time, dynamic assessment of cell therapy potency.
A synthetically made glycopeptide biologic has shown promise as a treatment for obesity-related diseases in mice.
The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
The global cell-based assays market is expected to grow due to increasing investments into cell-based research and a rise in chronic diseases.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
Researchers have shown that topoisomerase TOP2A eliminates negative supercoiling, causing an increase in the number of turns of DNA strands and impacting gene expression.
Epithelial cell communication depends on the side of the cell, which could have implications for understanding how cancer spreads.
A combination of computer simulations and fragment screening have uncovered 27 molecular binding sites on tubulin, a protein of the cell cytoskeleton.
According to new research, the biochip market will grow as a result of the rising demand for personalised medicine.
Researchers have shown how the MIS hormone can prevent ovulation in females, making it a potential new form of contraception.
